CAS Number183322-45-4
SynonymsTyrphostin AG 1517; N-(3-Bromophenyl)-6,7-dimethoxy-4-quinazolinamine hydrochloride (1:1); N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD-153035 HYDROCHLORIDE; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-, hydrochloride (1:1); N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride (1:1); PD153035 HCl; PD153035 HCL; SU-5271; AG1517; PD153035 Hydrochloride
Molecular FormulaC16H15BrClN3O2
Molecular Weight396.67
Purity96+%
Boiling Point472.1ºC at 760 mmHg
Melting Point265°C(lit.)
Appearancewhite to beige
EINECS0
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 183322-45-4 |
| Catalog No. | 2A-0160945 |
| Chinese Name | 6,7-二甲氧基-4-[N-(3-溴苯基)氨基]喹唑啉盐酸盐 |
| Synonyms | Tyrphostin AG 1517; N-(3-Bromophenyl)-6,7-dimethoxy-4-quinazolinamine hydrochloride (1:1); N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD-153035 HYDROCHLORIDE; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-, hydrochloride (1:1); N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride (1:1); PD153035 HCl; PD153035 HCL; SU-5271; AG1517; PD153035 Hydrochloride |
| Molecular Formula | C16H15BrClN3O2 |
| Molecular Weight | 396.67 |
| Purity | 96+ |
| Boiling Point | 472.1ºC at 760 mmHg |
| Melting Point | 265°C(lit.) |
| Appearance | white to beige |
| Water Solubility | DMSO: soluble2mg/mL, clear (warmed) |
| Storage Condition | 2-8°C |
| Application | PD153035 (ZM 252868; AG 1517; Tyrphostin AG 1517; SU 5271) is a potent EGFR inhibitor with Ki and IC50 values of 6 and 25 pM, respectively. |
| EINECS | 0 |
| HTC | 2933990090 |
| UN(IATA) | 0 |
| PubChem ID | 16331165 |
| MDL Number | C16H15BrClN3O2 |
| SMILES | COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC.Cl |
| InChI | InChI=1S/C16H14BrN3O2.ClH/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11;/h3-9H,1-2H3,(H,18,19,20);1H |
| InChI Key | ZJOKWAWPAPMNIM-UHFFFAOYSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/160945_1_183322_45_4.pdf |
| Bioactivity | PD153035 (ZM 252868;AG 1517;Tyrphostin AG 1517;SU 5271) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively. Related Catalog Research Areas >> Cancer Target EGFR:6 pM (Ki) EGFR:25 pM (IC50) In Vitro PD153035 inhibits EGF-stimulated receptor autophosphorylation in A431 human epidermoid carcinoma cells, with an IC50 of 14 nM[1]. PD 153035 has little effect on PDGFR, FGFR, CSF-1 receptor, the insulin receptor, or on src tyrosine kinases at concentrations as high as 50 μM. PD 153035 rapidly suppresses autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocks EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation[2]. PD153035 causes a dose-dependent growth inhibition of EGF receptor-positive cell lines, beginning at less than micromolar concentrations, and the IC50 is less than 1 pM in most cases[3]. In Vivo PD153035 levels in the plasma and tumor rise to 50 and 22 μM within 15 minutes following a single i.p. dose of 80 mg/kg. While the plasma levels of PD 153035 falls below 1 μM by 3 hours, in the tumors it remains at micromolar concentrations for at least 12 hours. The tyrosine phosphorylation of the EGF receptor is rapidly suppressed by 80-90% in the tumors[4]. Cell Assay Different EGF receptor-overexpressing cell lines (A43 1, Difi, MDA-MB-468, MDA-MB-231, DU145, SiHa, C4i, and MEl 80) are treated with PD153035 at increasing concentrations of 0.125-2.5 p.M. Growth inhibitory effect in monolayer cell culture is assessed[3]. Animal Admin Mice: Mice are injected with PD153035 (80 mg/kg) or vehicle and rumors are excised at 20 minutes and 180 minutes and extracts are prepared. Two mice are used for each time point and the experiment is repeated four times. Within each of the four experiments ANOVA is used to compare the inhibition by PD 153035 of the EGF-stimulation[3]. References [1]. Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. [2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. Chemical & Physical Properties Boiling Point 472.1ºC at 760 mmHg Melting Point 265°C(lit.) Molecular Formula C16H15BrClN3O2 Molecular Weight 396.666 Flash Point 239.3ºC Exact Mass 395.003601 PSA 56.27000 LogP 5.02810 Appearance of Characters white to beige InChIKey ZJOKWAWPAPMNIM-UHFFFAOYSA-N SMILES COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC.Cl Storage condition 2-8°C Water Solubility DMSO: soluble2mg/mL, clear (warmed) |
| Use of | PD153035 (ZM 252868;AG 1517;Tyrphostin AG 1517;SU 5271) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively. Properties Name N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine,hydrochloride Synonym More Synonyms PD153035 HCl Biological Activity Description PD153035 (ZM 252868;AG 1517;Tyrphostin AG 1517;SU 5271) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively. Related Catalog Research Areas >> Cancer EGFR:6 pM (Ki) EGFR:25 pM (IC50) Cell Assay Different EGF receptor-overexpressing cell lines (A43 1, Difi, MDA-MB-468, MDA-MB-231, DU145, SiHa, C4i, and MEl 80) are treated with PD153035 at increasing concentrations of 0.125-2.5 p.M. Growth inhibitory effect in monolayer cell culture is assessed[3]. References [2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. Chemical & Physical Properties Molecular Formula C16H15BrClN3O2 Exact Mass 395.003601 PSA 56.27000 LogP 5.02810 Appearance of Characters white to beige InChIKey ZJOKWAWPAPMNIM-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride) International air transport hazard regulations: Toxic solid, organic, n.o.s. (4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| N-(3-BROMO-2-NITROPHENYL)FORMAMIDE | 1215205-92-7 | 2A-0160936 |
| N-(3-BROMO-5-NITROPYRIDIN-2-YL)ACETAMIDE | 1065074-93-2 | 2A-0160939 |
| N-(3-BROMOBENZYL)-1-PHENYLETHANAMINE | 680185-60-8 | 2A-0160941 |
| N-(3-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE | 215797-81-2 | 2A-0160943 |
| N-(3-BROMOPHENYL)-6,7-DIMETHOXYQUINAZOLIN-4-AMINE | 153436-54-5 | 2A-0160944 |
| N-(3-BROMOPYRIDIN-4-YL)NITRAMIDE | 15367-14-3 | 2A-0160946 |
| N-(3-CHLORO-2-METHYLPHENYL)ACETAMIDE | 7463-35-6 | 2A-0160947 |
| N-(3-CHLORO-4-METHYLPHENYL)-2,2,2-TRIFLUOROACETAMIDE | 64694-83-3 | 2A-0160954 |
| N-(3-CHLOROPHENYL)-2-(((1-(4-CYANOBENZYL)-1H-IMIDAZOL-5-YL)METHYL)(2-HYDROXYETHYL)AMINO)ACETAMIDE | 253862-99-6 | 2A-0160958 |
| N-(3-CHLOROPHENYL)-2-((2-HYDROXYETHYL)AMINO)ACETAMIDE | 215649-70-0 | 2A-0160959 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS